Grindeks informs that the XXIII Nordic-Baltic Congress of Cardiology will be held in Riga, the Radisson Blu hotel, 16 – 18 June 2011, which is one of the most significant events in the medical field of cardiology in Latvia, which brings together more than 800 cardiologists from around 30 countries worldwide. Local pharmaceutical company Grindeks has become a silver sponsor and in the framework of the congress will organize a symposium “Energetic metabolism corrector role in the treatment of the coronary heart disease”. In the symposium scientific reading will be performed by prof. Andrejs Erglis, academician of Latvian Academy of Sciences prof. Ivars Kalvins and dr. med. Vilnis Dzerve.
According to the study on heart health status of the inhabitants of Latvia enforced by the Research Institute of Cardiology, University of Latvia and the Latvian Innovative Medicine Foundation, mortality from cardiovascular or coronary disease remains above 53% of all deaths in Latvia. The situation is similar also in other Baltic and CIS countries. For example, in Lithuania, the death rate from heart disease is the same as in Latvia, but in Russia – more than 57%.
The main cause of coronary heart disease is the deposition of cholesterol in the coronary artery wall, as a result the blood vessels become rigid, its diameter decreases, the blood supply to the heart is hindered and consequently, the heart receives less oxygen. The whole-body blood circulation is hindered, as the changes affect not only the heart but also other blood vessels. Coronary heart disease may manifest as angina, myocardial infarction, sudden death, arrhythmias.
Therefore, heart disease prevention and treatment is very important in maintaining and improving quality of life of each person. In its turn, energetic metabolism correctors or metabolic medications are highly effective in the treatment of coronary heart disease, as they have a positive effect on the body’s energetic metabolism, which restores oxygen supply and consumption process balance.
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
A range of Grindeks’ products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.
The Group consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries. Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”.
Head of the Communications Department
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505